Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05176678
Other study ID # NIS 184-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 4, 2021
Est. completion date July 11, 2023

Study information

Verified date June 2022
Source Natural Immune Systems Inc
Contact Gitte S Jensen, PhD
Phone 541-884-0112
Email gitte@nislabs.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A trial monitoring the immune effects in 24 people with 4 different doses (1 gram per day, 2 grams per day, 4 grams per day, 8 grams per day) of a natural plant-based protein hydrolysate.


Description:

The goal for this clinical proof-of-concept study is to compare immune effects of a novel plant-based peptide on IL-17, Th17 and related immunological mechanisms. An open-label, escalating dose study design monitoring immune effects in which healthy men and women take doses of a natural protein hydrolysate daily for 6 weeks. During the first 2 weeks, participants will consume 1 gram/day. For the next 2 weeks, participants will consume 2 grams/day. For the final 2 weeks, participants will be randomly assigned to consume either 4 grams/day or 8 grams/day. Blood samples are collected at baseline and every 2 weeks. The blood will be used for testing of the numbers of T lymphocytes that secrete Interleukin-17 after ex vivo cell cultures.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date July 11, 2023
Est. primary completion date November 4, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria: - 24 men and women - Eating a typical diet that does not exceed an estimated average of 9 grams of salt per day; - Willing to comply with a 24-hour wash-out period for vitamins and nutritional supplements; - Willing to comply with study procedures including: Maintaining a consistent diet and lifestyle routine throughout the study, Consistent habit of bland breakfasts on days of clinic visits, Abstaining from exercising and nutritional supplements on the morning of a study visit, Abstaining from use of coffee, tea, and soft drinks for at least one hour prior to a clinic visit; Abstaining from music, candy, gum, computer/cell phone use, during clinic visits. Exclusion Criteria: - Previous major gastrointestinal surgery Vaccination during past month; - Vaccination planned during study; - Cancer during past 12 months; - Chemotherapy during past 12 months; - Diagnosed with an autoimmune disorder; - Diagnosed with obstructive sleep apnea syndrome (OSAS); - Currently taking medication containing Levodopa (L-dopa); - Having received a cortisone shot within the past 6 months; - Taking anti-inflammatory medications on a daily basis; - Currently experiencing intense stressful events/life changes; - Currently in intensive athletic training (such as marathon runners); - An unusual sleep routine - Changes to nutritional supplements during the past month; - Currently taking Vitamin D at a dose higher than 1,000 IU/day; - Currently taking omega-3 at a dose higher than 1 gram/day; - Unwilling to maintain a constant intake of supplements over the duration of the study; - Women of childbearing potential: Pregnant, nursing, or trying to become pregnant; - Known food intolerances related to ingredients in active test product.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
1 gram of a protein hydrolysate
After 1 gram of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
2 grams of a protein hydrolysate
After 2 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
4 grams of a protein hydrolysate
After 4 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
8 grams of a protein hydrolysate
After 8 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.

Locations

Country Name City State
United States Gitte Jensen Klamath Falls Oregon

Sponsors (1)

Lead Sponsor Collaborator
Natural Immune Systems Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes to ex vivo PHA-mediated Th-17 cytokine secretion Ex vivo PBMC cultures with the mitogen PHA, followed by testing of cytokine production using a Th-17 Luminex array. 2 weeks, 4 weeks, 6 weeks
Secondary Evaluation of lymphocytes Ex vivo PBMC cultures with the mitogen PHA, followed by flow cytometry evaluation of T-cell differentiation and intracellular staining for Interleukin-17. 2 weeks, 4 weeks, 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT04092725 - Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Phase 1
Completed NCT04181008 - Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers Early Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT04406415 - Oral Nafamostat in Healthy Volunteers Phase 1
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Completed NCT02534753 - A Pharmacokinetics Study of Intravenous Ascorbic Acid Phase 1
Completed NCT01976078 - Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents N/A
Completed NCT01682408 - Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01214941 - Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol Phase 4
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01208155 - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets Phase 1
Completed NCT01260025 - Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor Phase 1
Completed NCT00983242 - Drug-Drug Interaction Between Colchicine and Verapamil ER Phase 1
Completed NCT00746499 - Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. Phase 1
Completed NCT00747721 - Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU Phase 1
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1
Completed NCT01055964 - a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients Phase 3
Completed NCT00856570 - A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects Phase 1
Completed NCT01276119 - The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males Phase 1